论文部分内容阅读
在香港创业板上市的医药及生物科技股份只有13家,其总市值为53亿港元,即平均每家仅4亿港元。这类股份的股价表现异常参差,约70％的预测市盈率在5～15倍之间,市场似乎已排除这类股份,认为在短期内给股东带来“惊喜”的可能性极小。它们的股价表现也呈个别发展。与上市价比较,中国生物制药(8027)升幅最大,超过85％,但它的预测市盈率也仅为10倍。康健国际(8138)跌幅最大,下挫82％。由于康健国际今年不须再为收购商誉做大量筹备,盈利有望重上2000万港元,预测市盈率也只是8倍左右。在香港上市的药业或生物科技股
There are only 13 pharmaceutical and biotech shares listed on the Hong Kong GEM, with a total market capitalization of HK $ 5.3 billion, or an average of only HK $ 400 million. The shares of such shares are exceptionally mixed, with about 70% of the forecast P / E at 5 to 15 times. The market seems to have ruled out such shares, saying there is very little chance of a “surprise” for shareholders in the short term. Their share price performance also showed individual development. Compared with the listing price, China Biopharmaceuticals (8027) recorded the largest increase of more than 85%, but its forecast PE of only 10x. Kang International (8138) the largest decline, down 82%. As Kang International this year no longer need to make a lot of preparation for the acquisition of goodwill, earnings are expected to re-enter 20 million Hong Kong dollars, the forecast price-earnings ratio is only about 8 times. Pharmaceutical or biotechnology stocks listed in Hong Kong